HLTH VanEck Global Hlthcr Ldrs ETF
- 10.660
- 0.0000.00%
Vertex Inks a Long-term Coverage Deal for Cystic Fibrosis Drugs in England
(RMD) - Analyzing ResMed's Short Interest
ResMed's (NYSE:RMD) short percent of float has fallen 3.28% since its last report. The company recently reported that it has 9.87 million shares sold short, which is 7.67% of all regular shares that a
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.Mul
Long-term Beneficiaries of AI, According to Goldman Sachs
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded
List of conversion stocks (Part 3) [List of parabolic signal conversion stocks]
List of selling conversion stocks in the market Code Stock Name Closing Price SAR Tokyo Prime <1662> Petroleum Resources 6280 6580 <1663> K&O Energy 3510 4310 <1944> Kinden 3301 3476 <2120> LIFULL 159 174 <2335> Cube System 1134 1155 <27>
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.
2024 Half-Year Recap | Top Performing Stocks: SMCI, NVDA and AI Supply Chain Stocks Are Listed
Looking back at the first half of 2024, the AI frenzy continued, and the US stock market soared, with the
After a round of buying that reflected the high-tech stock market in the US, there was a strong sense of stalemate.
The Nikkei average continued to rise, ending trading at ¥38,570.76, up 88.65 yen (with an estimated volume of 1.36 billion shares). Following the trend of buying high-tech stocks in the US market the previous day, buying centered on semiconductor and electronic component stocks, and buying led the market. The Nikkei average rose to ¥38,797.97 shortly after the start of trading. However, there is often a conflict between strength and weakness around the 25-day moving average, and there were profit-taking sales and waiting-to-buy-back sales, in addition to the US market being closed on June 19th in observance of Juneteenth (the commemoration of the emancipation of slaves).
(LLY) - Analyzing Eli Lilly and Co's Short Interest
Eli Lilly and Co's (NYSE:LLY) short percent of float has risen 14.06% since its last report. The company recently reported that it has 6.16 million shares sold short, which is 0.73% of all regular sha
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 20.87%. Currently, Vertex Pharmaceuticals
Eli Lilly's Oral Weight-loss Drug Is Potential Winner, Analyst Says
Dot-com Mega Caps Traded at a Higher Valuation Than Today's Mega Caps - GS
Least Shorted S&P 500 Stocks in May
Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 10 years by 19.61% on an annualized basis producing an average annual return of 30.51%. Currently, Eli Lilly and Co has a market c
13 Analysts Have This To Say About Vertex Pharmaceuticals
Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary o
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 -0.6% Cantor Fitzgerald $885 → $885 Reiterates Overweight → Overweight 06/12/2024 -0.6% Cantor
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 15.42% Argus Research $465 → $550 Maintains Buy 06/11/2024 -11.65% RBC Capital $424 → $421 Main
Looking Into Insulet's Recent Short Interest
Insulet's (NYSE:PODD) short percent of float has fallen 29.73% since its last report. The company recently reported that it has 2.99 million shares sold short, which is 5.72% of all regular shares tha
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $11,000 Today
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 4.44% on an annualized basis producing an average annual return of 17.24%. Currently, ResMed has a market capitalization of $31.